Skip to content

Study · Randomized controlled trial · n = 68 · 1997

4 results

[Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].

Abbou CC, Lucas C, Leblanc V

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie1 Dec 1997Cited by 10 (Europe PMC)

PMID9490144 (opens in a new tab)PepBankPUB-09490144
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In metastatic prostate cancer, the proportion with testosterone at or below 0.50 ng/mL did not differ significantly between triptorelin and leuprolide.

    In plain wordsIn metastatic prostate cancer, triptorelin and leuprolide did not differ significantly in the proportion reaching the testosterone threshold.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeTestosterone at or below 0.50 ng/mL
    Study

    n = 68

    Comparator
    Leuprolide 3.75 mg
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg monthly · intramuscular · 6 monthsAs given in this study (human).

    Measurements

    Testosterone at or below 0.50 ng/mL
    90%
    triptorelin first study time
    Testosterone at or below 0.50 ng/mL
    100%
    triptorelin second study time
    Testosterone at or below 0.50 ng/mL
    96%
    triptorelin third study time
    Testosterone at or below 0.50 ng/mL
    100%
    leuprolide first study time
    Testosterone at or below 0.50 ng/mL
    97%
    leuprolide second study time
    Testosterone at or below 0.50 ng/mL
    100%
    leuprolide third study time

    Source sentences

    Summary
    The percentages of patients with T < or = 0.50 ng/mL was not significantly different between the two groups and were equal to 100 and 90%, 97 and 100%, and 100 and 96% at the 3 study times, for leuprolide or triptorelin, respectively.
    3 context sentences
    Summary · context
    Main criterion: proportion of patients with T < or = 0.5 ng/mL.
    Summary · context
    68 patients received monthly injections for 6 months (randomization): either subcutaneous leuprolide 3.75 mg LP (n = 36), or intramuscular triptorelin 3.75 mg LP (n = 32).
    Summary · context
    (Flare-up prevention: nilutamide).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In metastatic prostate cancer, fewer triptorelin patients than leuprolide patients had testosterone below 0.30 ng/mL at one month.

    In plain wordsIn metastatic prostate cancer, fewer triptorelin patients than leuprolide patients reached the lower testosterone threshold at one month.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseTestosterone below 0.30 ng/mL at month one
    Study

    n = 68

    Comparator
    Leuprolide 3.75 mg
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg monthly · intramuscular · 6 monthsAs given in this study (human).

    Measurements

    Testosterone below 0.30 ng/mL
    60%
    triptorelin at 1 month
    Testosterone below 0.30 ng/mL
    86%
    leuprolide at 1 month

    Source sentences

    Summary
    The difference was significant at 1 month on complementary analysis at the limit of T < 0.30 ng/mL: 86% with leuprolide versus 60% with triptorelin (p = 0.02) and for mean plasma testosterone: 0.16 +/- 0.10 ng/mL versus 0.33 +/- 0.44 ng/mL, respectively (p = 0.02).
    2 context sentences
    Summary · context
    68 patients received monthly injections for 6 months (randomization): either subcutaneous leuprolide 3.75 mg LP (n = 36), or intramuscular triptorelin 3.75 mg LP (n = 32).
    Summary · context
    (Flare-up prevention: nilutamide).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In metastatic prostate cancer, mean testosterone at one month was higher with triptorelin than with leuprolide.

    In plain wordsIn metastatic prostate cancer, average testosterone at one month was higher with triptorelin than with leuprolide.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseMean testosterone at month one
    Study

    n = 68

    Comparator
    Leuprolide 3.75 mg
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg monthly · intramuscular · 6 monthsAs given in this study (human).

    Measurements

    Mean testosterone
    0.33 ng/mL
    triptorelin at 1 month
    Mean testosterone
    0.16 ng/mL
    leuprolide at 1 month

    Source sentences

    Summary
    The difference was significant at 1 month on complementary analysis at the limit of T < 0.30 ng/mL: 86% with leuprolide versus 60% with triptorelin (p = 0.02) and for mean plasma testosterone: 0.16 +/- 0.10 ng/mL versus 0.33 +/- 0.44 ng/mL, respectively (p = 0.02).
    2 context sentences
    Summary · context
    68 patients received monthly injections for 6 months (randomization): either subcutaneous leuprolide 3.75 mg LP (n = 36), or intramuscular triptorelin 3.75 mg LP (n = 32).
    Summary · context
    (Flare-up prevention: nilutamide).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In metastatic prostate cancer, subjective clinical efficacy did not differ significantly between triptorelin and leuprolide.

    In plain wordsIn metastatic prostate cancer, subjective clinical benefit did not differ significantly between triptorelin and leuprolide.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeSubjective clinical efficacy
    Study

    n = 68

    Comparator
    Leuprolide 3.75 mg
    Outcome group
    Overall treatment effect · Cancer
    Studied dose
    3.75 mg monthly · intramuscular · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The clinical subjective efficacy was not significantly different.
    2 context sentences
    Summary · context
    68 patients received monthly injections for 6 months (randomization): either subcutaneous leuprolide 3.75 mg LP (n = 36), or intramuscular triptorelin 3.75 mg LP (n = 32).
    Summary · context
    (Flare-up prevention: nilutamide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.